Tamoxifen and endometrial pathologies: A prospective study

Citation
M. Seoud et al., Tamoxifen and endometrial pathologies: A prospective study, GYNECOL ONC, 75(1), 1999, pp. 15-19
Citations number
36
Categorie Soggetti
Reproductive Medicine
Journal title
GYNECOLOGIC ONCOLOGY
ISSN journal
00908258 → ACNP
Volume
75
Issue
1
Year of publication
1999
Pages
15 - 19
Database
ISI
SICI code
0090-8258(199910)75:1<15:TAEPAP>2.0.ZU;2-9
Abstract
Objective. The purpose of this study was to prospectively follow a group of women with breast cancer, on tamoxifen, for the development of endometrial pathologies. Materials and methods. Eighty women with breast cancer, on tamoxifen, were prospectively followed every 6 months with pelvic examination, Pap smear, v aginal ultrasound, and endometrial biopsy. Results. Nine women were lost to follow-up prior to initiation of treatment and 4 refused biopsies, leaving 67 patients for evaluation. Fifty (74.6%) of the 67 patients were already on tamoxifen for a mean duration of 15.8 +/ - 16.6 months and had a baseline benign, unremarkable endometrium at the ti me of entry into the study. The total duration of treatment was 32.5 +/- 19 .6 months (median 30 months). The mean age of the patients was 51.7 +/- 9.9 years (median 52 years). Of the patients, 56.7% were postmenopausal. Sixty -three patients had a benign endometrium (mean age 51.8 +/- 10.1 years, mea n duration 33.1 +/- 19.6 months). Two patients had simple hyperplasia (mean age 43.5 years, duration 28.5 +/- 33.2 months), 1 patient had complex hype rplasia with atypia (age 57 years, duration 13 months), and another patient developed adenocarcinoma (grade 3) after 22 months. These 4 patients had a bnormal vaginal bleeding. Seven patients developed endometrial polyps (mean age 54.0 +/- 8.5 years, duration 36 +/- 24.2 months). The mean endometrial thickness for patients with histologically unremarkable and abnormal endom etrium was not significantly different (7.6 +/- 3.9 vs 8.8 +/- 5.0 mm, resp ectively) (median 7.0 mm for both groups). No endometrial thickness cutoff point reached statistical significance. The patient who developed endometri al cancer had a thickness of only 3 mm. Conclusion. All patients who developed an abnormal endometrium had abnormal vaginal bleeding. There was no correlation between endometrial thickness a nd endometrial pathology; thus the value of routine screening remains contr oversial. (C) 1999 Academic Press.